Peripartum cardiomyopathy (PPCM) is a potentially life-threatening disease that occurs in women of child-bearing age.
The development of heart failure (HF) in late pregnancy or the early puerperium, particularly in association with preeclampsia, is a rare and potentially life-threatening complication. The differential diagnosis in this setting includes PeriPartum CardioMyopathy (PPCM). Data on the incidence of PPCM are limited with variable ranges reported from different geographic regions with high incidences in Africa and Haiti. 1 -3 For western societies only retrospective questionnaires for the USA are available which report one in 2500-4000 pregnancies. 4, 5 To date, no data on the frequency of the disease in Europe exist at all.
Recently a position paper by the Working Group on PPCM from the Heart Failure Association of the European Society of Cardiology 6 proposed a revised definition of PPCM: (1) PPCM is an idiopathic cardiomyopathy presenting with HF secondary to left ventricular (LV) systolic dysfunction towards the end of pregnancy or in the months following delivery, where no other cause of HF is found.
(2) It is a diagnosis of exclusion with an ejection fraction (EF) nearly always reduced below 45% frequently but not always associated with LV dilation.
Although PPCM patients have a higher rate of spontaneous recovery of LV function compared with patients with other forms of non-ischaemic cardiomyopathy, 7 normalization of LV function at six months has been reported to occur in only 23-54% of patients. 2,3,8 -11 Factors predicting poor outcome in case series include degree of LV systolic dysfunction and LV dilation on presentation, presence of LV thrombus, as well as increase markers of inflammation and apoptosis. 5, 12 Research performed over recent years has achieved decisive advances in understanding aspects of the underlying molecular cascades that are dysregulated in PPCM. Among those, elevated pro-inflammatory serum markers such as sFas/Apo1, C-reactive protein, interferon gamma and interleukin 6, point to pro-inflammatory processes involved in the induction and the progression of PPCM and possibly impact on the prognosis. 6, 12 Recent work 13, 14 points to a possible involvement of a pathophysiological circuit involving unbalanced oxidative stress and subsequent enhanced cleavage of prolactin into an angiostatic and pro-apoptotic 16k Da subfragment which leads to massive endothelial damage and myocardial dysfunction. An important role of endothelial damage is further supported by the recent work of Walenta et al. 15 who demonstrated that endothelial microparticles are significantly increased in acute PPCM reflecting apoptosis with subsequent impaired microcirculation ( Figure 1 ) and by Arany et al. who showed that angiogenic imbalance in PPCM may depend on multiple factors including sFlt-1 and 16k Da prolactin. 16 In addition, genetic factors may contribute to a higher susceptibility to PPCM in patients with positive familial history of cardiomyopathy, who typically follow a more severe course of disease. 17, 18 PPCM from different ethnic groups or geographic regions might have different aetiologies and inducing factors. This is supported by the different prevalence of co-morbidities and their impact on outcome in our PPCM collectives. For example, concurrent hypertensive conditions such as gestational hypertension, pre-eclampsia and/or haemolysis, elevated liver enzymes, low platelet syndrome (HELLP) were frequent in PPCM patients in the USA, 9 in Europe and in Japan 19 but rarely present in African PPCM patients 6, 12 The African cohort studies, in fact, excluded patients with hypertension and preeclampsia as the researchers felt poorly managed hypertension leading to transient diastolic overload and flash pulmonary oedema associated with LV dysfunction was a separate entity. However, in western countries, pregnancy-associated hypertensive complications are frequently treated during pregnancy but are still associated with a higher risk of developing PPCM, suggesting additional pathomechanisms are present. Recent published experimental and clinical studies reported compelling evidence that pre-eclampsia may be a risk factor for PPCM by providing an extremely antiangiogenic environment. 16 In this edition of Obstetric Medicine, Basak et al. report on a patient with acute HF who also had severe pre-eclampsia. 20 The patient was an overweight primigravida and chronic smoker, who developed new onset hypertension in the third trimester and presented at 38 weeks gestation with a blood pressure (BP) of 180/110 mmHg. She also had significant proteinuria and headaches and a diagnosis of severe pre-eclampsia was made. Transthoracic echocardiography shortly after delivery showed poor LV function. The authors do not report on parameters such as functional mitral regurgitation or parameters of diastolic dysfunction. The LV dysfunction had normalized on echocardiography six weeks postpartum.
The authors suggest that the presence of marked systolic dysfunction represents an intrinsic failure of the ventricular contractility as seen in PPCM rather than impairment of LV response to increased afterload, i.e. the combination of increased systemic vascular resistance and contracted blood volume characteristic of cardiac failure secondary to preeclampsia. However, the remarkably rapid normalization of LV function would be more suggestive of HF secondary to hypertensive disease of pregnancy. A reliable distinction is not possible from the available data.
DOES THIS DIAGNOSTIC DISTINCTION MATTER TO THE MANAGING CLINICIAN OR THE PATIENT?
Acute onset PPCM with or without hypertension/preeclampsia requires intense management using intravenous diuretics, inotropic support, possibly including levosimentan and potentially mechanical assist devices. 6 On the basis of the mechanisms described above, preliminary data support the use of bromocriptine in combination with anticoagulation therapy in patients with PPCM, demonstrating improved survival and recovery of LV function. 14, 21 Standard HF therapy should be commenced including beta-blockers and angiotensin converting enzyme inhibitors. Chronic resynchronization, which is sometimes referred to as 'biventricular pacing,' is a form of therapy for congestive heart failure and should be considered in patients with symptoms consistent with New York Heart Association Functional Class (III/IV), LVEF,35% and widened QRS/left bundle branch Block. 22 Ongoing experimental research by several investigators around the world and the newly initiated registry on PPCM in all European Cardiac Society affiliated member countries via the ECS EUROOBS program (www.escardio.org) will hopefully contribute to increasing knowledge in this condition. 
